Mary Reumuth's most recent trade in Kala Pharmaceuticals Inc was a trade of 3,631 Common Stock done at an average price of $4.0 . Disclosure was reported to the exchange on June 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 4.01 per share. | 24 Jun 2025 | 3,631 | 62,100 (0%) | 0% | 4.0 | 14,560 | Common Stock |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 3.74 per share. | 03 Jun 2025 | 2,850 | 65,731 (0%) | 0% | 3.7 | 10,659 | Common Stock |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 45,200 | 45,200 | - | - | Stock Option (right to buy) | |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 10,100 | 70,287 (0%) | 0% | 0 | Common Stock | |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 7.63 per share. | 06 Jan 2025 | 1,706 | 68,581 (0%) | 0% | 7.6 | 13,017 | Common Stock |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 26 Jun 2024 | 4,163 | 60,187 (0%) | 0% | 4.7 | 19,774 | Common Stock |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 6.09 per share. | 31 May 2024 | 1,786 | 64,350 (0%) | 0% | 6.1 | 10,877 | Common Stock |
| Kala Pharmaceuticals Inc | Reumuth Mary | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 20,500 | 20,500 | - | - | Stock Option (right to buy) | |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 4,600 | 67,363 (0%) | 0% | 0 | Common Stock | |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 6.74 per share. | 04 Jan 2024 | 1,227 | 66,136 (0%) | 0% | 6.7 | 8,270 | Common Stock |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 432 | 432 | - | - | Stock Option (Right to Buy) | |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 9,525 | 11,943 (0%) | 0% | 0 | Common Stock | |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 28.53 per share. | 04 Jan 2023 | 60 | 11,883 (0%) | 0% | 28.5 | 1,712 | Common Stock |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 6.51 per share. | 26 Oct 2022 | 194 | 2,418 (0%) | 0% | 6.5 | 1,263 | Common Stock |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 0.37 per share. | 27 Jun 2022 | 2,613 | 130,595 (0%) | 0% | 0.4 | 967 | Common Stock |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 153,000 | 153,000 | - | - | Stock Option (right to buy) | |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 1.30 per share. | 03 Jan 2022 | 2,850 | 133,208 (0%) | 0% | 1.3 | 3,705 | Common Stock |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 1.80 per share. | 26 Oct 2021 | 9,449 | 136,058 (0%) | 0% | 1.8 | 17,008 | Common Stock |
| Kala Pharmaceuticals Inc | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 5.77 per share. | 28 Jun 2021 | 2,452 | 145,507 (0%) | 0% | 5.8 | 14,148 | Common Stock |
| Kala Pharmaceuticals Inc | Mary Reumuth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 90,667 | 90,667 | - | - | Stock Option (right to buy) | |
| Kala Pharmaceuticals Inc | Mary Reumuth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 22,666 | 147,959 (0%) | 0% | 0 | Common Stock | |
| Kala Pharmaceuticals Inc | Mary Reumuth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2020 | 61,000 | 125,293 (0%) | 0% | 0 | Common Stock |